Literature DB >> 2817958

Gall stones in homozygous sickle cell disease.

D K Webb, D T Dunn, G R Serjeant.   

Abstract

Mesh:

Year:  1989        PMID: 2817958      PMCID: PMC1792710          DOI: 10.1136/adc.64.9.1342

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  4 in total

1.  Cholelithiasis in patients with major sickle hemoglobinopathies.

Authors:  M B Rennels; M G Dunne; N J Grossman; A D Schwartz
Journal:  Am J Dis Child       Date:  1984-01

2.  Haematological change in sickle cell-haemoglobin C disease and in sickle cell-beta thalassaemia: a cohort study from birth.

Authors:  M C Stevens; G H Maude; M Beckford; Y Grandison; K Mason; B E Serjeant; B Taylor; J M Topley; G R Serjeant
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

3.  The development of haematological changes in homozygous sickle cell disease: a cohort study from birth to 6 years.

Authors:  G R Serjeant; Y Grandison; Y Lowrie; K Mason; J Phillips; B E Serjeant; S Vaidya
Journal:  Br J Haematol       Date:  1981-08       Impact factor: 6.998

4.  Gall stones in Jamaican children with homozygous sickle cell disease.

Authors:  D K Webb; J S Darby; D T Dunn; S I Terry; G R Serjeant
Journal:  Arch Dis Child       Date:  1989-05       Impact factor: 3.791

  4 in total
  1 in total

1.  Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort.

Authors:  Jéssica V G F Batista; Gabriela S Arcanjo; Thais H C Batista; Marcondes J Sobreira; Rodrigo M Santana; Igor F Domingos; Betânia L Hatzlhofer; Diego A Falcão; Diego A Pereira-Martins; Jéssica M Oliveira; Amanda S Araujo; Luana P M Laranjeira; Fernanda S Medeiros; Flávia P Albuquerque; Dulcinéia M Albuquerque; Magnun N Santos; Manuela F Hazin; Ana C Dos Anjos; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.